Isis gets $3.5M as antisense drug trial proceeds

05/12/2013 | Genetic Engineering & Biotechnology News

Biogen Idec paid Isis Pharmaceuticals a $3.5 million milestone fee after the dosing of the first infant with spinal muscular atrophy in a midstage trial of the antisense drug ISIS-SMN. The open-label study, which will involve eight infants with the condition, will be carried out in the U.S. and Canada.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX